Back to top
more

AbbVie (ABBV)

(Delayed Data from NYSE)

$201.68 USD

201.68
5,108,724

+1.21 (0.60%)

Updated Nov 5, 2024 04:00 PM ET

After-Market: $200.01 -1.67 (-0.83%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value D Growth B Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 35% (88 out of 250)

Industry: Large Cap Pharmaceuticals

Zacks News

Novartis (NVS) Gets Breakthrough Therapy Tag for Leukemia Drug

Novartis' (NVS) asciminib gets Breakthrough Therapy tag by the FDA for the treatment of adult patients with Ph+ CML in chronic phase, previously treated with two or more tyrosine kinase inhibitors.

Kinjel Shah headshot

Pharma Stock Roundup: PFE, MRK Q4 Earnings, AZN, JNJ Coronavirus Vaccine Updates

Several companies announce Q4 results. J&J (JNJ) and AstraZeneca (AZN) provide updates on their respective COVID-19 vaccines.

Zacks Value Trader Highlights: GameStop, Canadian Solar, AbbVie, Sony and Facebook

Zacks Value Trader Highlights: GameStop, Canadian Solar, AbbVie, Sony and Facebook

Tracey Ryniec headshot

My Best Advice to New Value Investors

New to stocks? 7 tips to becoming a better value investor.

Why AbbVie (ABBV) is a Great Dividend Stock Right Now

Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does AbbVie (ABBV) have what it takes? Let's find out.

Company News for Feb 4, 2021

Companies in The News Are: ABBV,SNE,HUM,SMG

AbbVie (ABBV) Q4 Earnings & Sales Top, 2021 Outlook Bright

AbbVie (ABBV) beats on fourth-quarter 2020 earnings and revenues. Shares up in pre-market trading.

AbbVie (ABBV) Q4 Earnings and Revenues Surpass Estimates

AbbVie (ABBV) delivered earnings and revenue surprises of 2.46% and 0.99%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

Amgen (AMGN) Q4 Earnings & Sales Top, 2021 Outlook Dull

Amgen (AMGN) beats Q4 estimates for both earnings and sales. Shares decline in after-hours trading.

Will Humira, Cancer Drugs Drive AbbVie (ABBV) Q4 Earnings?

AbbVie's (ABBV) Q4 top line is expected to have witnessed a recovery in demand amid improving global economies. However, resurgence of COVID-19 cases is likely to have hurt sales of physician-administered drugs.

Benjamin Rains headshot

Buy Pharma Giant AbbVie Stock Before Q4 Earnings for Dividend and Value?

Let's check out AbbVie to see if investors might want to buy the stock ahead of its fourth quarter fiscal 2020 financial release that's due out before the opening bell on Wednesday, Feb. 3...

Will Recovery in AbbVie's (ABBV) Earnings Continue in Q4?

Recovery in AbbVie's (ABBV) revenues is likely to have continued in the fourth quarter. Investors focus is likely to be on 2021 guidance when the company reports results in the wake of rising cases.

Kinjel Shah headshot

Pharma Stock Roundup: JNJ, NVS Q4 Earnings, MRK & LLY's Coronavirus Updates

J&J (JNJ) and Novartis (NVS) announce Q4 results. Merck (MRK), AbbVie (ABBV) & Pfizer (PFE) get EU approvals.

AbbVie (ABBV) Outpaces Stock Market Gains: What You Should Know

AbbVie (ABBV) closed the most recent trading day at $104.21, moving +1.38% from the previous trading session.

AbbVie (ABBV) Dips More Than Broader Markets: What You Should Know

AbbVie (ABBV) closed at $108.80 in the latest trading session, marking a -1.54% move from the prior day.

J&J (JNJ) Q4 Earnings & Sales Beat, 2021 Guidance Upbeat

J&J (JNJ) beats fourth-quarter 2020 estimates for both earnings and sales. It issues its adjusted earnings and sales outlook for 2021. Stock up.

J&J (JNJ) to Get the Ball Rolling for Pharma Q4 Earnings

J&J's (JNJ) Pharma segment is expected to have performed above market while continued procedure stabilization is expected to have benefited the Medical Devices segment in the fourth quarter.

AbbVie (ABBV) Gains But Lags Market: What You Should Know

In the latest trading session, AbbVie (ABBV) closed at $112.62, marking a +0.39% move from the previous day.

Bausch Health (BHC) Dry Eye Treatment Study Enrollment Complete

Bausch Health (BHC) and Novaliq GmbH complete enrollment in first of the two phase III studies evaluating NOV03 to treat the signs and symptoms of Dry eye disease associated with MGD.

Sheraz Mian headshot

Top Stock Reports for Novartis, QUALCOMM & Accenture

Today's Research Daily features new research reports on 16 major stocks, including Novartis (NVS), QUALCOMM (QCOM), and Accenture (ACN).

Editas (EDIT) Up More Than 100% in Past 3 Months: Here's Why

Editas' (EDIT) lead candidate EDIT-101, that employs CRISPR gene editing to treat LCA10, holds potential. The company is also developing EDIT-301 for treating SCD.

AbbVie (ABBV) Dips More Than Broader Markets: What You Should Know

AbbVie (ABBV) closed at $111.63 in the latest trading session, marking a -0.73% move from the prior day.

AbbVie (ABBV) Inks Deal to Acquire Medical Device Company

AbbVie (ABBV) signs an agreement to acquire privately held Cypris Medical, including the latter's Xact device which is used for performing face and neck lifts.

AbbVie (ABBV) Outpaces Stock Market Gains: What You Should Know

AbbVie (ABBV) closed at $109.78 in the latest trading session, marking a +0.7% move from the prior day.

Novartis (NVS) In-Licenses Anti-PD-1 Antibody from BeiGene

Novartis (NVS) in-licenses BeiGene's anti-PD-1 monoclonal antibody, tislelizumab, in major markets outside of China.